Repository logo
 

Multi-site Neurogenin3 Phosphorylation Controls Pancreatic Endocrine Differentiation

Published version
Peer-reviewed

Change log

Authors

Azzarelli, R 
Hurley, C 
Sznurkowska, MK 
Hardwick, L 

Abstract

The proneural transcription factor Neurogenin3 (Ngn3) plays a critical role in pancreatic endocrine cell differentiation, although regulation of Ngn3 protein is largely unexplored. Here we demonstrate that Ngn3 protein undergoes cyclin-dependent kinase (Cdk)-mediated phosphorylation on multiple serine-proline sites. Replacing wild-type protein with a phosphomutant form of Ngn3 increases α cell generation, the earliest endocrine cell type to be formed in the developing pancreas. Moreover, un(der)phosphorylated Ngn3 maintains insulin expression in adult β cells in the presence of elevated c-Myc and enhances endocrine specification during ductal reprogramming. Mechanistically, preventing multi-site phosphorylation enhances both Ngn3 stability and DNA binding, promoting the increased expression of target genes that drive differentiation. Therefore, multi-site phosphorylation of Ngn3 controls its ability to promote pancreatic endocrine differentiation and to maintain β cell function in the presence of pro-proliferation cues and could be manipulated to promote and maintain endocrine differentiation in vitro and in vivo.

Description

Keywords

diabetes, endocrine differentiation, insulinoma, neurogenin3, pancreatic development, pancreatic organoids, proneural bHLH transcription factors, β cells

Journal Title

Developmental Cell

Conference Name

Journal ISSN

1534-5807
1878-1551

Volume Title

41

Publisher

Elsevier (Cell Press)
Sponsorship
Medical Research Council (MR/K018329/1)
Leukaemia & Lymphoma Research (12029)
MRC (MR/K50127X/1)
Cancer Research UK (C14303/A17197)
Cancer Research UK (CB4230)
Wellcome Trust (103805/Z/14/Z)
Medical Research Council (MR/L021129/1)
Medical Research Council (MC_PC_12009)
Wellcome Trust (097922/Z/11/Z)
Wellcome Trust (098357/Z/12/Z)
Medical Research Council (MR/M008975/1)
This work was supported by the MRC Research GrantMR/K018329/1; the Rosetrees Trust (to A.P. and R.A.); the MRC Research Grant MR/L021129/1 and core support from the Wellcome Trust and the MRC Cambridge Stem Cell Institute (to A.P. and F.A.); the MRC Doctoral Training Awards (to L.M., L.H., and M.S.); the CRUK studentship (to C. Hurley); the Wellcome Trust 098357/Z/12/Z (to B.D.S. and R.A.); and the Wellcome Trust 097922/Z/11/Z and the Clinical Research Infrastructure Single-Cell Facility (MR/M008975/1) (to B.G.). D.W. and R.K. are CRUK funded; G.E. is CRUK A12077 funded. M.H. is a Sir Henry Dale fellow and is supported by the Wellcome Trust 104151/Z/14/A and the Royal Society.